These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24274581)

  • 1. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands.
    Kotsikorou E; Sharir H; Shore DM; Hurst DP; Lynch DL; Madrigal KE; Heynen-Genel S; Milan LB; Chung TD; Seltzman HH; Bai Y; Caron MG; Barak LS; Croatt MP; Abood ME; Reggio PH
    Biochemistry; 2013 Dec; 52(52):9456-69. PubMed ID: 24274581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands.
    Kotsikorou E; Madrigal KE; Hurst DP; Sharir H; Lynch DL; Heynen-Genel S; Milan LB; Chung TD; Seltzman HH; Bai Y; Caron MG; Barak L; Abood ME; Reggio PH
    Biochemistry; 2011 Jun; 50(25):5633-47. PubMed ID: 21534610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor.
    Lingerfelt MA; Zhao P; Sharir HP; Hurst DP; Reggio PH; Abood ME
    Biochemistry; 2017 Jan; 56(3):473-486. PubMed ID: 28005346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
    Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
    J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
    Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
    J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
    Sharir H; Abood ME
    Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Activity Relationship of the GPR55 Antagonist, CID16020046.
    Brown AJ; Castellano-Pellicena I; Haslam CP; Nichols PL; Dowell SJ
    Pharmacology; 2018; 102(5-6):324-331. PubMed ID: 30296786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
    Anavi-Goffer S; Irving AJ; Ross RA
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
    Rempel V; Volz N; Gläser F; Nieger M; Bräse S; Müller CE
    J Med Chem; 2013 Jun; 56(11):4798-810. PubMed ID: 23679955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of orphan GPCRs, GPR35 and GPR55.
    Shore DM; Reggio PH
    Front Pharmacol; 2015; 6():69. PubMed ID: 25926795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances Towards The Discovery of GPR55 Ligands.
    Morales P; Jagerovic N
    Curr Med Chem; 2016; 23(20):2087-100. PubMed ID: 27109575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors.
    Zhao P; Abood ME
    Life Sci; 2013 Mar; 92(8-9):453-7. PubMed ID: 22820167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55.
    Kargl J; Balenga N; Parzmair GP; Brown AJ; Heinemann A; Waldhoer M
    J Biol Chem; 2012 Dec; 287(53):44234-48. PubMed ID: 23161546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists.
    Yrjölä S; Parkkari T; Navia-Paldanius D; Laitinen T; Kaczor AA; Kokkola T; Adusei-Mensah F; Savinainen JR; Laitinen JT; Poso A; Alexander A; Penman J; Stott L; Anskat M; Irving AJ; Nevalainen TJ
    Eur J Med Chem; 2016 Jan; 107():119-32. PubMed ID: 26575458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
    Nevalainen T; Irving AJ
    Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model.
    Fatemi I; Abdollahi A; Shamsizadeh A; Allahtavakoli M; Roohbakhsh A
    Acta Neuropsychiatr; 2021 Feb; 33(1):15-21. PubMed ID: 32967746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55.
    Elbegdorj O; Westkaemper RB; Zhang Y
    J Mol Graph Model; 2013 Feb; 39():50-60. PubMed ID: 23220281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship.
    Figuerola-Asencio L; Morales P; Zhao P; Hurst DP; Sayed SS; Colón KL; Gómez-Cañas M; Fernández-Ruiz J; Croatt MP; Reggio PH; Abood ME; Jagerovic N
    ACS Med Chem Lett; 2023 Jan; 14(1):18-25. PubMed ID: 36655130
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.